Immunocore presents new data on tebentafusp in metastatic cutaneous melanoma (mCM) and uveal melanoma (mUM) at the Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting

Tebentafusp in combination with checkpoint inhibitors had acceptable safety profile; preliminary evidence of clinical activity in anti-PD(L)1 relapsed/refractory mCM

 Survival benefit for tebentafusp monotherapy in mUM observed for both high and low gp100 protein tumor expression 

 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 9 November 2021) Immunocore Holdings Plc (Nasdaq: IMCR), a late-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease, will present six posters at the Society for Immunotherapy of Cancer (SITC) 36^th Annual Meeting, to be held in Washington, D.C. and virtually between November 10-14^th.